MCRB vs. PALI

The year-to-date returns for both stocks are quite close, with MCRB having a -57.34% return and PALI slightly lower at -58.35%.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Seres Therapeutics, Inc. (MCRB) and Palisade Bio, Inc. (PALI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current MCRB Sharpe Ratio is -0.53, which is higher than the PALI Sharpe Ratio of -0.79. The chart below compares the historical Sharpe Ratios of MCRB and PALI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither MCRB nor PALI has paid dividends to shareholders.

The maximum MCRB drawdown since its inception was -99.34%, roughly equal to the maximum PALI drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for MCRB and PALI.

Seres Therapeutics, Inc. (MCRB) has a higher volatility of 30.05% compared to Palisade Bio, Inc. (PALI) at 21.41%. This indicates that MCRB's price experiences larger fluctuations and is considered to be riskier than PALI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Seres Therapeutics, Inc. and Palisade Bio, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.